查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1379173

血液恶性肿瘤市场：2023-2028 年全球产业趋势、份额、规模、成长、机会与预测

Hematologic Malignancies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3个工作天内

价格

抽象的

2022年，全球血液恶性肿瘤市场规模达到553亿美元。展望未来， IMARC Group预计到2028年市场规模将达到932亿美元，2022-2028年复合年增长率（CAGR）为9.1%。

血液恶性肿瘤，如淋巴瘤、白血病和多发性骨髓瘤，是造血细胞的癌症。这些细胞包括用于凝血伤口的血小板、携带氧气的红血球 (RBC) 和用于免疫保护的白血球 (WBC)，这些细胞源自骨髓中的造血干细胞和祖细胞。血液恶性肿瘤可以透过显微镜、细胞遗传学、免疫表型、流式细胞仪、萤光原位杂交 (FISH)、聚合酶炼式反应 (PCR) 和基因表现谱等测试来诊断。如今，世界各地有多种药物可用于基于诊断测试的治疗，包括抗肿瘤抗生素、组蛋白去乙酰化酶抑制剂和 Janus 激酶 (JAK) 抑制剂。

血液恶性肿瘤市场趋势：

老年族群中急性髓性白血病（AML）的发生率相对较高。这与预期寿命的延长相结合，是推动全球血液恶性肿瘤药物需求的关键因素之一。除此之外，随着免疫组织化学（IHC）的进步，透过将组织样本暴露于针对细胞分子和抗原的各种抗体，可以准确诊断血液恶性肿瘤。这反过来又加强了市场的成长。此外，人们对早期诊断的认识不断提高，加上诊断方式的改进，也促进了市场的成长。除此之外，手术治疗还可用于组织诊断和治疗淋巴瘤併发症，例如穿孔、阻塞和狭窄。这与多种新疗法的推出以及高价药物的多个标籤扩展（例如 CAR T 细胞疗法和 brexucabtagene autoleuce）相结合，正在推动市场成长。此外，正在进行的为晚期血液恶性肿瘤患者引入先进药物的临床研究预计将在未来几年推动市场发展。

本报告回答的关键问题：

  • 迄今为止，全球血液恶性肿瘤市场表现如何，未来几年将如何表现？
  • COVID-19 对全球血液恶性肿瘤市场有何影响？
  • 主要区域市场有哪些？
  • 依类型划分市场是怎么样的？
  • 基于该疗法的市场区隔是什么？
  • 基于最终用户的市场区隔是什么？
  • 产业价值链的各个阶段是什么？
  • 该行业的关键驱动因素和挑战是什么？
  • 全球血液恶性肿瘤市场的结构如何？谁是主要参与者？
  • 产业竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球血液恶性肿瘤市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：按类型分類的市场细分

  • 白血病
    • 市场走向
    • 市场预测
  • 淋巴瘤
    • 市场走向
    • 市场预测
  • 多发骨髓瘤
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：透过疗法进行市场区隔

  • 化疗
    • 市场走向
    • 市场预测
  • 放射治疗
    • 市场走向
    • 市场预测
  • 免疫疗法
    • 市场走向
    • 市场预测
  • 干细胞移植
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：最终用户的市场区隔

  • 医院
    • 市场走向
    • 市场预测
  • 诊断中心
    • 市场走向
    • 市场预测
  • 研究中心
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：按地区分類的市场区隔

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 按国家/地区分類的市场细分
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AbbVie Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co. Inc
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
Product Code: SR112023A4133

Abstract

The global hematologic malignancies market size reached US$ 55.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 93.2 Billion by 2028, exhibiting a growth rate (CAGR) of 9.1% during 2022-2028.

Hematologic malignancies, such as lymphoma, leukemia, and multiple myeloma, are cancers of blood-producing cells. These cells comprise platelets for wound clotting, red blood cells (RBCs) to carry oxygen, and white blood cells (WBCs) for immune protection, which originate from hematopoietic stem and progenitor cells in the bone marrow. Hematologic malignancies can be diagnosed using tests like microscopy, cytogenetics, immunophenotyping, flow cytometry, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and gene expression profiling. Nowadays, several drugs, including antitumor antibiotics, histone deacetylase inhibitors, and Janus kinase (JAK) inhibitors, are available around the world for treatment based on diagnostic tests.

Hematologic Malignancies Market Trends:

The incidence of acute myeloid leukemia (AML) is relatively higher among the geriatric population. This, in confluence with the increasing life expectancy, represents one of the key factors catalyzing the demand for hematologic malignancies drugs across the globe. Besides this, with advances in immunohistochemistry (IHC), hematologic malignancies can be diagnosed accurately by exposing tissue samples to various antibodies directed against cell molecules and antigens. This, in turn, is strengthening the growth of the market. Moreover, the rising awareness about early diagnosis, along with improving diagnostic modalities, is contributing to market growth. Apart from this, surgical therapy is available for tissue diagnosis and treatment of lymphoma complications, such as perforation, obstruction, and stricture. This, in confluence with the launch of several novel therapies and multiple label expansions of premium-priced agents, such as CAR T-cell therapies and brexucabtagene autoleuce, is propelling the market growth. Furthermore, ongoing clinical research studies to introduce advanced drugs for patients with advanced hematologic malignancies are anticipated to drive the market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hematologic malignancies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, therapy and end user.

Breakup by Type:

Leukemia

Lymphoma

Multiple Myeloma

Others

Breakup by Therapy:

Chemotherapy

Radiotherapy

Immunotherapy

Stem Cell Transplantation

Others

Breakup by End User:

Hospitals

Diagnostics Centers

Research Centers

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Key Questions Answered in This Report:

  • How has the global hematologic malignancies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global hematologic malignancies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the therapy?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global hematologic malignancies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hematologic Malignancies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Leukemia
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Lymphoma
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Multiple Myeloma
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Therapy

  • 7.1 Chemotherapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Radiotherapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Immunotherapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Stem Cell Transplantation
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostics Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Research Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bristol-Myers Squibb Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche Ltd
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GlaxoSmithKline plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Johnson & Johnson
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Merck & Co. Inc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Novartis AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Sanofi S.A.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Takeda Pharmaceutical Company Limited
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hematologic Malignancies Market: Major Drivers and Challenges
  • Figure 2: Global: Hematologic Malignancies Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Hematologic Malignancies Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Hematologic Malignancies Market: Breakup by Type (in %), 2022
  • Figure 5: Global: Hematologic Malignancies Market: Breakup by Therapy (in %), 2022
  • Figure 6: Global: Hematologic Malignancies Market: Breakup by End User (in %), 2022
  • Figure 7: Global: Hematologic Malignancies Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Hematologic Malignancies (Leukemia) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Hematologic Malignancies (Leukemia) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Hematologic Malignancies (Lymphoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Hematologic Malignancies (Lymphoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Hematologic Malignancies (Multiple Myeloma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Hematologic Malignancies (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Hematologic Malignancies (Other Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Hematologic Malignancies (Other Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Hematologic Malignancies (Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Hematologic Malignancies (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Hematologic Malignancies (Radiotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Hematologic Malignancies (Radiotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Hematologic Malignancies (Immunotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Hematologic Malignancies (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Hematologic Malignancies (Stem Cell Transplantation) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Hematologic Malignancies (Stem Cell Transplantation) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Hematologic Malignancies (Other Therapies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Hematologic Malignancies (Other Therapies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Hematologic Malignancies (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Hematologic Malignancies (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Hematologic Malignancies (Diagnostics Centers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Hematologic Malignancies (Diagnostics Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Hematologic Malignancies (Research Centers) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Hematologic Malignancies (Research Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Global: Hematologic Malignancies (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Global: Hematologic Malignancies (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: North America: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: North America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: United States: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: United States: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Canada: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Canada: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Asia-Pacific: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Asia-Pacific: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: China: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: China: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Japan: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Japan: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: India: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: India: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: South Korea: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: South Korea: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Australia: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Australia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Indonesia: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Indonesia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Europe: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Europe: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Germany: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Germany: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: France: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: France: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: United Kingdom: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: United Kingdom: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Italy: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Italy: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Spain: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Spain: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Russia: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Russia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Latin America: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Latin America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Brazil: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Brazil: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Mexico: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Mexico: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 80: Middle East and Africa: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 81: Middle East and Africa: Hematologic Malignancies Market: Breakup by Country (in %), 2022
  • Figure 82: Middle East and Africa: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 83: Global: Hematologic Malignancies Industry: SWOT Analysis
  • Figure 84: Global: Hematologic Malignancies Industry: Value Chain Analysis
  • Figure 85: Global: Hematologic Malignancies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hematologic Malignancies Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Hematologic Malignancies Market Forecast: Breakup by Type (in Million US$), 2023-2028
  • Table 3: Global: Hematologic Malignancies Market Forecast: Breakup by Therapy (in Million US$), 2023-2028
  • Table 4: Global: Hematologic Malignancies Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Hematologic Malignancies Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Hematologic Malignancies Market: Competitive Structure
  • Table 7: Global: Hematologic Malignancies Market: Key Players